Literature DB >> 33186336

Comment on "Meropenem, Cefepime, and Piperacillin Protein Binding in Patient Samples".

Uwe Liebchen1, Christoph Dorn2, Martin Kees3, Selina Schiesser4, Florian Hitzenbichler4, Frieder Kees2, Michael Paal5.   

Abstract

Entities:  

Year:  2020        PMID： 33186336     DOI： 10.1097/FTD.0000000000000809

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN： 0163-4356            Impact factor:   3.681


× No keyword cloud information.
  3 in total

1.  Target Site Pharmacokinetics of Meropenem: Measurement in Human Explanted Lung Tissue by Bronchoalveolar Lavage, Microdialysis, and Homogenized Lung Tissue.

Authors:  Michael Paal; Christina Scharf; Ann Katrin Denninger; Luis Ilia; Charlotte Kloft; Nikolaus Kneidinger; Uwe Liebchen; Sebastian Michel; Christian Schneider; Sebastian Schröpf; Carina Schuster; Michael Vogeser; Ferdinand Weinelt; Johannes Zander; Michael Zoller; Ines Schroeder
Journal:  Antimicrob Agents Chemother       Date:  2021-09-27       Impact factor: 5.191

2.  Combination of Pharmacokinetic and Pathogen Susceptibility Information To Optimize Meropenem Treatment of Gram-Negative Infections in Critically Ill Patients.

Authors:  Uwe Liebchen; Ferdinand Weinelt; Jette Jung; Robin Michelet; Christina Scharf; Ines Schroeder; Michael Paal; Michael Zoller; Charlotte Kloft
Journal:  Antimicrob Agents Chemother       Date:  2021-12-06       Impact factor: 5.938

3.  Physiologically Based Pharmacokinetic Modeling of Meropenem in Preterm and Term Infants.

Authors:  Samit Ganguly; Andrea N Edginton; Jacqueline G Gerhart; Michael Cohen-Wolkowiez; Rachel G Greenberg; Daniel Gonzalez
Journal:  Clin Pharmacokinet       Date:  2021-06-22       Impact factor: 5.577
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.